Literature DB >> 21751815

New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.

Maurizio Anzini1, Salvatore Valenti, Carlo Braile, Andrea Cappelli, Salvatore Vomero, Stefano Alcaro, Francesco Ortuso, Luciana Marinelli, Vittorio Limongelli, Ettore Novellino, Laura Betti, Gino Giannaccini, Antonio Lucacchini, Simona Daniele, Claudia Martini, Carla Ghelardini, Lorenzo Di Cesare Mannelli, Gianluca Giorgi, Maria Paola Mascia, Giovanni Biggio.   

Abstract

3-Substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds were synthesized as central benzodiazepine receptor (CBR) ligands. Most of the compounds showed high affinity for bovine and human CBR, their K(i) values spanning from the low nanomolar to the submicromolar range. In particular, imidazoester 5f was able to promote a massive flow of (36)Cl(-) in rat cerebrocortical synaptoneurosomes overlapping its efficacy profile with that of a typical full agonist. Compound 5f was then examined in mice for its pharmacological effects where it proved to be a safe anxiolytic agent devoid of the unpleasant myorelaxant and amnesic effects of the classical 1,4-benzodiazepines. Moreover, the selectivity of some selected compounds has been assessed in recombinant α(1)β(2)γ(2)L, α(2)β(1)γ(2)L, and α(5)β(2)γ(2)L human GABA(A) receptors. Finally, some compounds were submitted to molecular docking calculations along with molecular dynamics simulations in the Cromer's GABA(A) homology model.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21751815     DOI: 10.1021/jm2001597

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease.

Authors:  Stefano Fiorucci; Pasquale Rapacciuolo; Bianca Fiorillo; Rosalinda Roselli; Silvia Marchianò; Cristina Di Giorgio; Martina Bordoni; Rachele Bellini; Chiara Cassiano; Paolo Conflitti; Bruno Catalanotti; Vittorio Limongelli; Valentina Sepe; Michele Biagioli; Angela Zampella
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

2.  Improved scale-up synthesis and purification of clinical asthma candidate MIDD0301.

Authors:  Daniel E Knutson; Rashid Roni; Yeunus Mian; James M Cook; Douglas C Stafford; Leggy A Arnold
Journal:  Org Process Res Dev       Date:  2020-07-29       Impact factor: 3.317

3.  Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases.

Authors:  Carmen Festa; Simona De Marino; Adriana Carino; Valentina Sepe; Silvia Marchianò; Sabrina Cipriani; Francesco S Di Leva; Vittorio Limongelli; Maria C Monti; Angela Capolupo; Eleonora Distrutti; Stefano Fiorucci; Angela Zampella
Journal:  Front Pharmacol       Date:  2017-03-30       Impact factor: 5.810

4.  Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists.

Authors:  Simona De Marino; Adriana Carino; Dario Masullo; Claudia Finamore; Silvia Marchianò; Sabrina Cipriani; Francesco Saverio Di Leva; Bruno Catalanotti; Ettore Novellino; Vittorio Limongelli; Stefano Fiorucci; Angela Zampella
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.